Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of MORAb-003 in platinum-sensitive epithelial ovarian cancer in first relapse
2009-015825-36Phase 2Terminated
- Sponsor
- Morphotek
- Start
- Oct 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of farletuzumab in epithelial ovarian cancer (EOC), sponsored by Morphotek. Primary endpoint: CA125 levels. Started Oct 2009; status: terminated.
02
Drugs
farletuzumab
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2009-015825-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015825-36.